Merck Millipore Introduces New Excipient for Solubility/Bioavailability Enhancement

News
Article

Merck Millipore has introduced a new solubility/bioavailability enhancement excipient, Parteck SLC, which has a unique pore structure that enables higher loading of amorphous APIs, thereby, improving dissolution rates and increasing drug solubility.

Merck Millipore, the life-science division of Merck, has developed a new solubility/bioavailability enhancement excipient, Parteck SLC, which has a unique pore structure that enables higher loading of amorphous APIs, thereby, improving dissolution rates and increasing drug solubility.

Parteck SLC’s mesopores (2–7 nm) create a surface area of up to 1000 m2/g for depositing an API in its amorphous form needed for supersaturation. The internal surface area of Parteck SLC is also easily accessible and the API is kept stable. A user-friendly particle size (5–25 μm) and bulk density (0.32 g/ml) allow easy loading, tableting, or capsule creation.

Parteck SLC is not a novel excipient. Regulatory requirements, therefore, remain the same as it conforms to the silica monographs of Ph Eur and USP. Parteck SLC comes with ready-to-use documentation in CTD-format. Feasibility studies on loading and in vitro dissolution are also available.

Matthias Bucerius, PhD, head of pharmaceutical raw materials, commented in a press statement, that many promising drug candidates fail to get pass the development hurdle because of poor bioavailability and this problem causes significant loss of time and resources to companies. The addition of Parteck SLC to Merck Millipore’s portfolio of excipients provides drug developers with a new option to increase the solubility/bioavailability of their APIs or reformulate their drugs to extend product lifecycle.

Source: Merck Millipore

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content